Apr. 16 at 5:38 AM
$AKBA the proposal II just increases the max number of shares that akba can have from 375 mm to 525 mm, this is standard practice for a massively growing biotech. This is not a dilution event so just filter out all the FUD out there regarding that. Main thing is they need to be able to raise cash when opportunities arise ie used for phase 3 trial expenses, acquisitions, and even growing their work / sales force. They were already getting close to the max shares cap and need more flexibility. Of course they are not stupid enough to dilute shares at
$1.5 a share, but they want the flexibility to get some more cash on hand at say
$10,
$20,
$30 a share etc. This move also signifies that q1 2026 Vafseo revenue most likely had a blowout quarter and they can be more aggressive in their growth strategy. I may even vote yes for this proposal with my shares, if q1 2026 Vafseo revenue is high enough (
$20+ mm). Shorts will spin anything towards the bad, this is just standard procedure non event.
